Table 1.
IC50 (μM) | ||||||||
---|---|---|---|---|---|---|---|---|
Compound | NOX1 | NOX2 | NOX3 | NOX4 | NOX5 | DUOX1 | DUOX2 | XO/AO |
GKT136901 (92, 118) | 0.16a,b | 1530a,b | 0.17a,b | 0.45a,b | >30,000b | |||
GKT137831 (5) | 0.14a,b | 1750a,b | 0.11a,b | 0.41a,b | >100b | |||
ML171 (58) | 0.25c | 5.00c | 3.00c | 5.00c | 5.50 | |||
VAS2870 (52, 55) | 0.77d | |||||||
VAS3947 (181) | 12.0a | 2.00d | 13.00a | n.s.e | ||||
Celastrol (76) | 0.41c | 0.59c | 2.79c | 3.13c | >100 | |||
Ebselen (76, 164) | 0.15c | 0.50c | >50.0c | 0.70a | n.s.f | |||
Perhexiline (55, 85) | 3.0d | n.s.f | ||||||
Grindelic acid (89) | >20.0d | 2.06c | >20.0c | n.s.g | ||||
NOX2ds-tat (36) | n.s.a,h | 0.74a | n.sa,h | n.s.h | ||||
NOXA1ds (143) | 0.02a | n.s.a,h | n.s.a,h | n.s.a,h | n.s.h | |||
Fulvene-5 (15) | ∼5.00c | ∼5.00c | ||||||
ACD 084 (89) | >5.00c | 3.08c | >5.00c | n.s.i | ||||
Phenantridinones (19) | 0.17c | n.s.h | ||||||
Shionogi (55) | 0.56d | |||||||
S17834 | ||||||||
Imipramin blue (117) | ∼5.00 |
IC50 values of NOX inhibitors for different NOX isoforms and XO or AO activity are presented as determined in different cellular or cell-free assays as described in the respective publication and indicated with the superscription. The IC50 values that suggest relative NOX isoform selectivity are shown in bold. Only some inhibitors were tested for XO inhibition or ROS-scavenging effects, and inhibition was not significant (n.s.) for some of these compounds.
IC50 values were determined in acell-free or lysate assay; bKi were published; coverexpressing cells; dnative cells; eno significant inhibition for concentrations of approximately 30 μM or f100 μM, g20 μM, h10 μM, i5 μM.
AO, antioxidant; DUOX, dual oxidase; IC50, concentration with 50% inhibition of activity; NADPH, nicotinamide adenine dinucleotide phosphate; NOX, catalytic subunit of NADPH oxidases; NOX2ds, NOX2 docking sequence; XO, xanthine oxidase.